Navigation Links
Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
Date:1/12/2009

RIDGEFIELD, Conn., Jan. 12 /PRNewswire/ -- Boehringer Ingelheim today announced the appointment of Albert Ros as executive vice president of Sales and Marketing for the company's Prescription Medicines Business. In his new role, Ros will lead the U.S. sales and marketing strategy of Boehringer Ingelheim's core brands.

"We are pleased to have Albert in such an important leadership role," said J. Martin Carroll, President and Chief Executive Officer, Boehringer Ingelheim Corporation. "Albert is a valuable member of the Boehringer Ingelheim team and he possesses an impressive range of global sales and marketing experience."

Ros has been with Boehringer Ingelheim for 14 years and previously served as Head of Boehringer Ingelheim's Corporate Division for Marketing of Prescription Medicines. In this position, which he held since 2005, Ros led the development of four global products including Spiriva(R), Flomax(R), Mirapex(R) and Micardis(R). Previously, Ros served as the country manager for Boehringer Ingelheim Brazil and the business unit head of Boehringer Ingelheim Spain.

Ros earned a pharmacy degree from the University of Barcelona, a master's degree in business administration from ESADE Business School in Barcelona, and a post graduate degree in general management from IESE Business School in Barcelona. Ros and his wife and three sons will relocate to Ridgefield, Connecticut in early 2009.

About Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. For more information, please visit http://us.boehringer-ingelheim.com.


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Washington, DC (PRWEB) , ... April 28, 2017 ... ... Unplanned Pregnancy (The National Campaign) announces its support for the Access to ... by Sen. Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce its ... has been in place since the RBMA was founded in 1968 with all board ... Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for Clinical ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... ... cardiac or hERG liability could substantially improve drug safety and minimize the cost ... provided for validating ion channel inhibition using cell lines and for cardiac toxicity ...
(Date:4/28/2017)... UTAH (PRWEB) , ... April 28, 2017 , ... ... Account Manager for the North East region. Côté has 20+ years of experience ... Prior to Phytomer, Côté worked with an array of high-end cosmetic brands, retail ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
Breaking Medicine Technology: